AU2003215878A1 - Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue - Google Patents

Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue

Info

Publication number
AU2003215878A1
AU2003215878A1 AU2003215878A AU2003215878A AU2003215878A1 AU 2003215878 A1 AU2003215878 A1 AU 2003215878A1 AU 2003215878 A AU2003215878 A AU 2003215878A AU 2003215878 A AU2003215878 A AU 2003215878A AU 2003215878 A1 AU2003215878 A1 AU 2003215878A1
Authority
AU
Australia
Prior art keywords
therapeutic
diagnostic
cosmetic agent
stinging cells
delivering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003215878A
Other languages
English (en)
Other versions
AU2003215878A8 (en
Inventor
Shimon Eckhouse
Tamar Lotan
Esther Shaoul
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NanoCyte Inc
Original Assignee
NanoCyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NanoCyte Inc filed Critical NanoCyte Inc
Publication of AU2003215878A8 publication Critical patent/AU2003215878A8/xx
Publication of AU2003215878A1 publication Critical patent/AU2003215878A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/86—Products or compounds obtained by genetic engineering
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003215878A 2002-03-26 2003-03-20 Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue Abandoned AU2003215878A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36726102P 2002-03-26 2002-03-26
US60/367,261 2002-03-26
PCT/IL2003/000241 WO2003079967A2 (en) 2002-03-26 2003-03-20 Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue

Publications (2)

Publication Number Publication Date
AU2003215878A8 AU2003215878A8 (en) 2003-10-08
AU2003215878A1 true AU2003215878A1 (en) 2003-10-08

Family

ID=28454843

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003215878A Abandoned AU2003215878A1 (en) 2002-03-26 2003-03-20 Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue

Country Status (7)

Country Link
US (2) US7611723B2 (US07611723-20091103-C00003.png)
EP (1) EP1519755B1 (US07611723-20091103-C00003.png)
AT (1) ATE394125T1 (US07611723-20091103-C00003.png)
AU (1) AU2003215878A1 (US07611723-20091103-C00003.png)
DE (1) DE60320793D1 (US07611723-20091103-C00003.png)
IL (1) IL164191A0 (US07611723-20091103-C00003.png)
WO (1) WO2003079967A2 (US07611723-20091103-C00003.png)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7632522B2 (en) 2000-09-28 2009-12-15 Nanocyte Inc. Use of stinging cells/capsules for the delivery of active agents to keratinous substances
IL155097A0 (en) 2000-09-28 2003-10-31 Nanocyte Inc Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
US20060222656A1 (en) * 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
EP1519755B1 (en) 2002-03-26 2008-05-07 Nanocyte Inc. Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue
JP2007503205A (ja) * 2003-08-22 2007-02-22 ニュークレオニクス・インコーポレイテッド 多コンパートメント真核生物発現系
US7146203B2 (en) 2003-12-18 2006-12-05 Elliot Botvinick Implantable biosensor and methods of use thereof
US8834862B2 (en) 2005-04-19 2014-09-16 Nanocyte Inc. Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent
US8013211B2 (en) 2005-07-07 2011-09-06 FuturaGene Israel, Ltd. Compositions and methods comprising stinging capsules/cells for delivering a biologically active agent into a plant cell
DE102007035238A1 (de) * 2007-07-27 2009-01-29 Christian-Albrechts-Universität Zu Kiel Biologisches Effektmonitoring mittels transgener Hydra
US20210161092A1 (en) * 2016-02-16 2021-06-03 Ajikumar Parayil KUMARAN Secondary metabolite screening system
WO2018178969A1 (en) * 2017-03-28 2018-10-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Transformed organisms with stinging cells expressing an exogenous protein of interest
WO2024006793A1 (en) * 2022-06-29 2024-01-04 Battelle Memorial Institute Nematocysts as natural microinjectors

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US614960A (en) * 1898-11-29 Hair-clipper
US3321188A (en) * 1965-10-04 1967-05-23 Broadway Imp S Paint mixing device
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5459047A (en) * 1986-07-01 1995-10-17 Genetics Institute, Inc. BMP-6 proteins
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5073488A (en) 1988-11-29 1991-12-17 Minnesota Mining And Manufacturing Company Rapid method for determining efficacy of a sterilization cycle and rapid read-out biological indicator
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5162378A (en) 1990-04-20 1992-11-10 Revlon Consumer Products Corporation Silicone containing water-in-oil microemulsions having increased salt content
US5885260A (en) 1991-05-30 1999-03-23 Mehl, Sr.; Thomas L. Freeze-dried liposome delivery system for application of skin treatment agents
US5641508A (en) * 1994-01-13 1997-06-24 Anticancer, Inc. Method for delivering melanin to hair follicles
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5362442A (en) 1993-07-22 1994-11-08 2920913 Canada Inc. Method for sterilizing products with gamma radiation
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
US5885211A (en) 1993-11-15 1999-03-23 Spectrix, Inc. Microporation of human skin for monitoring the concentration of an analyte
FR2729855A1 (fr) * 1995-01-26 1996-08-02 Oreal Utilisation d'un antagoniste de cgrp dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
US6416960B1 (en) 1996-08-08 2002-07-09 Prolume, Ltd. Detection and visualization of neoplastic tissues and other tissues
CA2789115C (en) 1996-12-31 2014-04-29 Altea Therapeutics Corporation Microporation of tissue for delivery of bioactive agents
US6338837B1 (en) 1997-05-29 2002-01-15 Nidaria Technology Ltd. Compositions and methods for inhibiting nematocyst discharge
US6406709B1 (en) 1997-05-29 2002-06-18 Nidaria Technology Ltd. Method for inhibiting nematocyst discharge
US6132747A (en) 1997-05-29 2000-10-17 Nidaria Technology Ltd. Compositions and methods for inhibiting nematocyst discharge
US6022316A (en) 1998-03-06 2000-02-08 Spectrx, Inc. Apparatus and method for electroporation of microporated tissue for enhancing flux rates for monitoring and delivery applications
US6173202B1 (en) 1998-03-06 2001-01-09 Spectrx, Inc. Method and apparatus for enhancing flux rates of a fluid in a microporated biological tissue
ATE375752T1 (de) 1998-03-06 2007-11-15 Spectrx Inc Integrierte gewebeporations-, flüssigkeitsammel- und analysevorrichtung
US6630001B2 (en) 1998-06-24 2003-10-07 International Heart Institute Of Montana Foundation Compliant dehyrated tissue for implantation and process of making the same
PT1124607E (pt) 1998-07-14 2008-12-31 Altea Therapeutics Corp Remoção controlada de membranas biológicas por carga pirotécnica, para transporte transmembranar
WO2000004821A1 (en) 1998-07-21 2000-02-03 Spectrx, Inc. Fluid management in a continuous fluid collection and sensor device
AU5004299A (en) 1998-07-21 2000-02-14 Altea Technologies, Inc. System and method for continuous analyte monitoring
EP1112021A1 (en) 1998-09-10 2001-07-04 Spectrx, Inc. Attribute compensation for analyte detection and/or continuous monitoring
AU1728701A (en) 1999-11-29 2001-06-04 Nidaria Technology Ltd. A composition and method for inhibiting polar capsule discharge and protecting asubject from nematocyst sting
WO2001078504A2 (en) 2000-04-17 2001-10-25 Organ Recovery Systems, Inc. Novel warming method of cryopreserved specimens
US20070281037A9 (en) * 2000-09-28 2007-12-06 Nanocyte Inc. Sterile preparations and compositions including stinging capsules and methods of producing and using same
IL155097A0 (en) 2000-09-28 2003-10-31 Nanocyte Inc Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
US7632522B2 (en) * 2000-09-28 2009-12-15 Nanocyte Inc. Use of stinging cells/capsules for the delivery of active agents to keratinous substances
EP1519755B1 (en) 2002-03-26 2008-05-07 Nanocyte Inc. Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue
US20030189850A1 (en) 2002-04-09 2003-10-09 Toyo Boseki Kabushiki Kaisha Cell array system
JP2004344036A (ja) 2003-05-21 2004-12-09 Fujitsu Ltd 物質導入装置及び物質導入システム
US20050181978A1 (en) * 2003-11-20 2005-08-18 Rasmus Rojkjaer Therapeutic use of factor XI
US20060099272A1 (en) * 2004-11-05 2006-05-11 Nanocyte Inc. Compositions and kits including dehydrated stinging capsules and methods of producing and using same
EP1851662A2 (en) 2005-02-24 2007-11-07 Xeround Systems Ltd. Method and apparatus for distributed data management in a switching network
US8834862B2 (en) 2005-04-19 2014-09-16 Nanocyte Inc. Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent

Also Published As

Publication number Publication date
DE60320793D1 (de) 2008-06-19
US8337868B2 (en) 2012-12-25
EP1519755A4 (en) 2006-11-22
WO2003079967A3 (en) 2005-02-03
IL164191A0 (en) 2005-12-18
ATE394125T1 (de) 2008-05-15
US7611723B2 (en) 2009-11-03
EP1519755B1 (en) 2008-05-07
US20100111869A1 (en) 2010-05-06
EP1519755A2 (en) 2005-04-06
WO2003079967A2 (en) 2003-10-02
AU2003215878A8 (en) 2003-10-08
US20060039897A1 (en) 2006-02-23

Similar Documents

Publication Publication Date Title
NZ603330A (en) Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies
AU2003209259A1 (en) Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof
AU2002354893A1 (en) Methods of generating human cardiac cells and tissues and uses thereof
AU2003215878A1 (en) Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue
IL173369A0 (en) Pharmaceutical combination of g-csf and plgf useful for blood stem cell
AU2003269820A1 (en) Miniature biological fuel cell that is operational under physiological conditions, and associated devices and methods
MY144292A (en) Method of reducing oral tissue inflammation using magnolia extract
EP1575528A4 (en) TREATMENT PROTECTIVE CYTOKINS FOR THE PROTECTION, RECOVERY AND STRENGTHENING OF RESPECTIVE CELLS, TISSUE AND ORGANS
WO2007013065A3 (en) Electrical stimulation of blood vessels
BR9910251A (pt) Estimulação hematopoiética
AU2003239609A1 (en) 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same
PL312219A1 (en) Application of nona- and decapeptides in obtaining a therapeutic agent for fighting against aids
AU2003273276A8 (en) Methods and compositions for the preservation of cells, tissues or organs in the vitreous state
WO2002026191A3 (en) Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
AU7634801A (en) Three-dimensional skin model
AU1154701A (en) Hair transplantation
AU8180001A (en) Human growth hormone to stimulate mobilization of pluripotent hematopoietic stemcells
EP1782824A3 (de) Pharmazeutische Zusammensetzungen, die Diaminooxidase enthalten
WO2001079706A3 (en) Electrolytic cell
WO2004039832A3 (en) Leptin-related peptides
MXPA05003818A (es) Perfilamiento de la expresion genica de muestras ffpe.
WO2003033678A3 (en) Methods of using deacetylase inhibitors to promote cell differentiation and regeneration
WO2002089832A3 (en) Pharmaceutical compositions for preventing or treating th1 and th2 cell related diseases by modulating the th1/th2 ratio.
AU3946197A (en) Cosmetic, dermatological and pharmaceutical use of a terminalia catappa extract
AU2001283199A1 (en) Methods and compositions for the diagnosis and treatment of brown adipose cell disorders

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase